Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 5/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19597969 | 0.83 | NPC1 (0.48) | HTTLMNAALDH1A1NPSR1 | |
| SCHEMBL11108539 | 0.82 | LTA4H (0.53) | L3MBTL1MAPK1MAPTTDP1HTT | |
| SCHEMBL15837402 | 0.81 | L3MBTL1 (0.44) | L3MBTL1MAPK1MAPTTDP1HTT | |
| SCHEMBL16231687 | 0.81 | L3MBTL1 (0.45) | L3MBTL1MAPK1MAPTTDP1HTT | |
| SCHEMBL14719395 | 0.80 | SLC6A4 (0.44) | L3MBTL1MAPK1MAPTTDP1HTT | |
| SCHEMBL14729707 | 0.80 | SQOR (0.51) | L3MBTL1MAPK1MAPTTDP1HTT | |
| SCHEMBL15837139 | 0.80 | MPO (0.50) | L3MBTL1MAPK1MAPTTDP1HTT | |
| SCHEMBL14718731 | 0.80 | HTR2C (0.43) | L3MBTL1MAPK1MAPTTDP1HTT | |
| SCHEMBL15821308 | 0.80 | L3MBTL1 (0.44) | L3MBTL1MAPK1MAPTTDP1HTT | |
| SCHEMBL14719551 | 0.79 | L3MBTL1 (0.44) | L3MBTL1MAPK1MAPTTDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202399-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | disclosed |
| US-9931340-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-03 | — | — | US | disclosed |
| EP-2748149-B9 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170107226-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9290456-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | L3MBTL1 4060/4885MAPK1 3374/4885MAPT 2770/4885 |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | L3MBTL1 4285/4885MAPK1 1645/4885MAPT 2902/4885 |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | L3MBTL1 4285/4885MAPK1 1645/4885MAPT 2902/4885 |
| US-10202399-B2 | Dihydroxy aromatic heterocyclic compound | DAO, DDO, DDC | L3MBTL1 3346/4885MAPK1 1762/4885MAPT 2990/4885 |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | L3MBTL1 4285/4885MAPK1 1645/4885MAPT 2902/4885 |
| US-20170107226-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | DAO, DDO, DDC | L3MBTL1 3346/4885MAPK1 1762/4885MAPT 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.